Structural basis of binding of fluorescent, site-specific dansylated amino acids to human serum albumin

Journal of Structural Biology

Volumn 174, Issue 1, 2011, Pages 84-91

  Ryan, Ali J ^a   Ghuman, Jamie ^a   Zunszain, Patricia A ^a   Chung, Chun wa ^b   Curry, Stephen ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Dansylated amino acids; Human serum albumin; Protein drug interactions; X ray crystallography

Indexed keywords

AMINO ACID; DANSYL L ARGININE; DANSYL L ASPARAGINE; DANSYL L GLUTAMATE; DANSYL L NORVALINE; DANSYL L PHENYLALANINE; DANSYL L SARCOSINE; DANSYLATED AMINO ACID; FATTY ACID; HUMAN SERUM ALBUMIN; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING SITE; FLUORESCENCE; PRIORITY JOURNAL;

ARGININE; ASPARAGINE; DANSYL COMPOUNDS; GLUTAMATES; HUMANS; PHENYLALANINE; PROTEIN BINDING; SARCOSINE; SERUM ALBUMIN;

EID: 79952446257     PISSN: 10478477     EISSN: 10958657     Source Type: Journal    
DOI: 10.1016/j.jsb.2010.10.004     Document Type: Article

References (42)

1. Antolini L., Menabue L., Sola M., Battaglia L.P., Corradi A.B. The effect of a dansyl group on the co-ordinative ability of N-protected amino acids. Part 2. Binary copper(II) complexes and their pyridine and 2, 2'-bipyridine adducts. Crystal and molecular structure of the complexes aquabis (N-dansylglycinato-0)bis(pyridine)copper(11) and (2, 2'-bipyridine)-(N-dansylglycinato-NO)(methanol)copper(II), and neutral N-dansylglycine. J. Chem. Soc. Dalton Trans. 1986, 1367-1373.
2. Bhattacharya A.A., Curry S., Franks N.P. Binding of the general anesthetics propofol and halothane to human serum albumin: high-resolution crystal structures. J. Biol. Chem. 2000, 275:38731-38738.
3. Bhattacharya A.A., Grüne T., Curry S. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J. Mol. Biol. 2000, 303:721-732.
4. Birkett D.J., Myers S.P., Sudlow G. Effects of fatty acids on two specific drug binding sites on human serum albumin. Mol. Pharmacol. 1977, 13:987-992.
5. Brodersen R. Binding of bilirubin to albumin. CRC Crit. Rev. Clin. Lab. Sci. 1980, 11:305-399.
6. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S., Read R.J., Rice L.M., Simonson T., Warren G.L. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. 1998, D54:905-921.
7. Carter D.C., Ho J.X. Structure of serum albumin. Adv. Protein Chem. 1994, 45:152-203.
8. Chen Y.M., Guo L.H. Fluorescence study on site-specific binding of perfluoroalkyl acids to human serum albumin. Arch. Toxicol. 2009, 83:255-261.
9. Collaborative Computer Project No.4 The CCP4 suite: programs for protein crystallography. Acta Crystallogr. 1994, D50:760-763.
10. Curry S. Lessons from the crystallographic analysis of small molecule binding to human serum albumin. Drug Metab. Pharmacokinet. 2009, 24:342-357.
11. Curry S., Brick P., Franks N.P. Fatty acid binding to human serum albumin: new insights from crystallographic studies. Biochim. Biophys. Acta 1999, 1441:131-140.
12. Curry S., Mandelkow H., Brick P., Franks N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat. Struct. Biol. 1998, 5:827-835.
13. Fletcher D.A., McMeeking R.F., Parkin D. The United Kingdom chemical database service. J. Chem. Inf. Comput. Sci. 1996, 36:746-749.
14. Ghuman J., Zunszain P.A., Petitpas I., Bhattacharya A.A., Otagiri M., Curry S. Structural basis of the drug-binding specificity of human serum albumin. J. Mol. Biol. 2005, 353:38-52.
15. He X.M., Carter D.C. Atomic structure and chemistry of human serum albumin. Nature 1992, 358:209-215.
16. Hein K.L., Kragh-Hansen U., Morth J.P., Jeppesen M.D., Otzen D., Moller J.V., Nissen P. Crystallographic analysis reveals a unique lidocaine binding site on human serum albumin. J. Struct. Biol. 2010, 171:353-360.
17. Jones T.A., Zou J.Y., Cowan S.W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these maps. Acta Crystallogr. 1991, A47:110-119.
18. Kragh-Hansen U., Watanabe H., Nakajou K., Iwao Y., Otagiri M. Chain length-dependent binding of fatty acid anions to human serum albumin studied by site-directed mutagenesis. J. Mol. Biol. 2006, 363:702-712.
19. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26:283-291.
20. Lejon S., Cramer J.F., Nordberg P. Structural basis for the binding of naproxen to human serum albumin in the presence of fatty acids and the GA module. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2008, 64:64-69.
21. Lissi E., Alicia Biasutti M., Abuin E., Leon L. A fluorescence study of human serum albumin binding sites modification by hypochlorite. J. Photochem. Photobiol. B 2009, 94:77-81.
22. Mathias U., Jung M. Determination of drug-serum protein interactions via fluorescence polarization measurements. Anal. Bioanal. Chem. 2007, 388:1147-1156.
23. Nakajou K., Watanabe H., Kragh-Hansen U., Maruyama T., Otagiri M. The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants. Biochim. Biophys. Acta 2003, 1623:88-97.
24. Peters T. All about Albumin: Biochemistry, Genetics and Medical Applications 1995, Academic Press, San Diego.
25. Petitpas I., Bhattacharya A.A., Twine S., East M., Curry S. Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I. J. Biol. Chem. 2001, 276:22804-22809.
26. Petitpas I., Petersen C.E., Ha C.E., Bhattacharya A.A., Zunszain P.A., Ghuman J., Bhagavan N.V., Curry S. Structural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemia. Proc. Natl. Acad. Sci. USA 2003, 100:6440-6445.
27. Richieri G.V., Kleinfeld A.M. Unbound free fatty acid levels in human serum. J. Lipid Res. 1995, 36:229-240.
28. Sakai T., Yamasaki K., Sako T., Kragh-Hansen U., Suenaga A., Otagiri M. Interaction mechanism between indoxyl sulfate, a typical uremic toxin bound to site II, and ligands bound to site I of human serum albumin. Pharm. Res. 2001, 18:520-524.
29. Simard J.R., Zunszain P.A., Hamilton J.A., Curry S. Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis. J. Mol. Biol. 2006, 361:336-351.
30. Simard J.R., Zunszain P.A., Ha C.E., Yang J.S., Bhagavan N.V., Petitpas I., Curry S., Hamilton J.A. Locating high-affinity fatty acid-binding sites on albumin by X-ray crystallography and NMR spectroscopy. Proc. Natl. Acad. Sci. USA 2005, 102:17958-17963.
31. Sogami M., Foster J.F. Isomerization reactions of charcoal-defatted bovine plasma albumin. The N-F transition and acid expansion. Biochemistry 1968, 7:2172-2182.
32. Spector A.A. Plasma albumin as a lipoprotein. Biochemistry and Biology of Plasma Lipoproteins 1986, 247-279. Dekker, New York. A.M. Scanu, A.A. Spector (Eds.).
33. Sudlow G., Birkett D.J., Wade D.N. The characterization of two specific drug binding sites on human serum albumin. Mol. Pharmacol. 1975, 11:824-832.
34. Sudlow G., Birkett D.J., Wade D.N. Further characterization of specific drug binding sites on human serum albumin. Mol. Pharmacol. 1976, 12:1052-1061.
35. Thorarensen A., Sarver R.W., Tian F., Ho A., Romero D.L., Marotti K.R. Human serum albumin binding assay based on displacement of a non selective fluorescent inhibitor. Bioorg. Med. Chem. Lett. 2007, 17:4646-4649.
36. Vorum H., Honoré B. Influence of fatty acids on the binding of warfarin and phenprocoumon to human serum albumin with relation to anticoagulant therapy. J. Pharm. Pharmacol. 1996, 48:870-875.
37. Wardell M., Wang Z., Ho J.X., Robert J., Ruker F., Ruble J., Carter D.C. The atomic structure of human methemalbumin at 1.9Å. Biochem. Biophys. Res. Commun. 2002, 291:813-819.
38. Wells R., Hammond K., Lamola A.A., Blumberg W.E. Relationships of bilirubin binding parameters. Clin. Chem. 1982, 28:432-439.
39. Yamasaki K., Maruyama T., Kragh-Hansen U., Otagiri M. Characterization of site I on human serum albumin: concept about the structure of a drug binding site. Biochim. Biophys. Acta 1996, 1295:147-157.
40. Zhu L., Yang F., Chen L., Meehan E.J., Huang M. A new drug binding subsite on human serum albumin and drug-drug interaction studied by X-ray crystallography. J. Struct. Biol. 2008, 162:40-49.
41. Zunszain P., Ghuman J., Mcdonagh A., Curry S. Crystallographic analysis of human serum albumin complexed with 4Z, 15E-bilirubin-IXalpha. J. Mol. Biol. 2008, 381:394-406.
42. Zunszain P.A., Ghuman J., Komatsu T., Tsuchida E., Curry S. Crystal structural analysis of human serum albumin complexed with hemin and fatty acid. BMC Struct. Biol. 2003, 3:6.